Literature DB >> 15067299

Cortical hyperostosis in an infant on prolonged prostaglandin infusion: case report and literature review.

Sithembiso Velaphi1, Antoinette Cilliers, Elaine Beckh-Arnold, Mantoa Mokhachane, Ramatsimele Mphahlele, John Pettifor.   

Abstract

The common side effects associated with the use of prostaglandins in newborn infants include apnoea, hyperthermia, diarrhoea, skin flushing and oedema. Periosteal reaction or cortical thickening of the bones, also known as cortical hyperostosis, is associated with a prolonged use of prostaglandins. This is a radiological diagnosis; therefore, its occurrence is most likely underestimated. We describe an infant who developed cortical hyperostosis simulating osteomyelitis with elevated alkaline phosphatase. The radiologic changes were initially attributed to congenital syphilis. This occurred after a prolonged infusion of prostaglandin E(1) for a cyanotic congenital heart disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067299     DOI: 10.1038/sj.jp.7211050

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  3 in total

1.  Spontaneous dissection of the arterial duct during continuous infusion of prostaglandin E1 in a neonate with aortic arch interruption.

Authors:  Nao Inoue; Satoshi Yasukochi; Kiyohiro Takigiku; Hikoro Matsui; Kohta Takei; Yusuke Nakano; Tessyu Otagiri; Yuichiro Hashida; Yoshifumi Ogiso; Yoshiyuki Maekawa; Kentaro Umezu; Takahiko Sakamoto; Yorikazu Harada
Journal:  J Echocardiogr       Date:  2013-07-31

2.  A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders.

Authors:  Robert C Gensure; Outi Mäkitie; Catherine Barclay; Catherine Chan; Steven R Depalma; Murat Bastepe; Hilal Abuzahra; Richard Couper; Stefan Mundlos; David Sillence; Leena Ala Kokko; Jonathan G Seidman; William G Cole; Harald Jüppner
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

3.  The Osteogenesis Imperfecta Type V Mutant BRIL/IFITM5 Promotes Transcriptional Activation of MEF2, NFATc, and NR4A in Osteoblasts.

Authors:  Vincent Maranda; Marie-Hélène Gaumond; Pierre Moffatt
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.